Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Recalling Some Champix Products after Detecting Carcinogen
July 29, 2021
- Toray, Veritas Tie Up to Discover Small Molecule Drugs Targeting mRNA
July 29, 2021
- Shionogi in Talks with Vietnam Govt on Vaccine Tech Transfer
July 29, 2021
- European Panel Rejects Kyowa Kirin’s Parkinson’s Med
July 29, 2021
- Kyowa Kirin Files Bardoxolone Methyl in Japan for Alport Syndrome
July 29, 2021
- Ayumi Adjusts Shipments for RA Med Rimatil Impacted by Peers' Unstable Supplies
July 29, 2021
- Towa’s Shipment Curbs Now Affect 319 Products, Active Vitamin Analogs Too
July 29, 2021
- Keytruda Keeps Top Drug Crown in FY2020 despite Double-Digit Dip: Tally
July 28, 2021
- MSD Urges Expansion of Exclusion Criteria for Spillover Rules as Repeated Cuts Hit Keytruda
July 28, 2021
- Meiji to Sell JV Stake to Dong-A, but Will Continue Biosimilar Collaboration
July 28, 2021
- Takeda, PeptiDream Expand Collaboration into Neurodegenerative Disease Area
July 28, 2021
- Daiichi Sankyo Espha, Meiji Pharma Launch Cymbalta Generics
July 28, 2021
- AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
July 27, 2021
- Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
- Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021
- Moderna Vaccine’s Minimum Age Lowered to 12 in Japan
July 27, 2021
- Lenvima/Keytruda Gets Full US Approval for Endometrial Carcinoma
July 27, 2021
- Meiji Pharma Licenses Stelara Biosimilar to India’s Intas
July 26, 2021
- Rohto Begins Japan PIII for Topical Ganciclovir in CMV Corneal Endotheliitis
July 21, 2021
- Relugolix Combination Drug Approved in EU for Uterine Fibroids
July 21, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…